PTK2 and renal carcinoma: Structural optimization studies led to the generation of a quinazoline-based derivative, of α1-adrenoreceptors antagonist, DZ-50, that was shown to overcome anoikis resistance in human renal cancer cells by disrupting integrin/FAK-mediated cell survival pathways in vitro and in vivo [3].